A novel second-generation platinum derivative and evaluation of its anti-cancer potential

Basit Öğe Kaydı
dc.authoridYİLMAZ, HABİBE/0000-0003-1106-0458
dc.authorwosidYİLMAZ, HABİBE/AAG-5274-2019
dc.contributor.authorYilmaz, Habibe
dc.contributor.authorSanlier, Senay Hamarat
dc.date.accessioned2024-06-12T11:12:28Z
dc.date.available2024-06-12T11:12:28Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractCisplatin is the primary anti-cancer agent for the treatment of most solid tumors. However, platinum-based anti-cancer chemotherapy produces severe side effects due to its poor specificity. There are a broad interest and literature base for a novel mechanism of action on platinum derivatives. Additionally, combining cisplatin with histone deacetylase inhibitors (HDACi) such as 4-hydroxybenzoic acid derivatives showed promising results in treating solid tumors. Here we aimed to conjugate 4-hydroxybenzoic acid with platinum to obtain a novel platinum derivative that can overcome cisplatin resistance. Cis-4-hydroxyphenylplatinum(II)diamine compound was synthesized under mild conditions and characterized. Cytotoxicity assay was performed on SKOV3-Luc and A549-Luc cells. Hemocompatibility and serum protein binding analysis were performed. Treatment potential was evaluated in xenograft tumor models. Biodistribution was tested on tumor-bearing mice via Pt analysis in organs with ICP-MS, ex vivo. In this study, cis-4-hydroxyphenylplatinum (II) diamine was synthesized with a yield of 62%. The MTT assay on A549-Luc and SKOV3-Luc cell lines resulted in IC50 values of 17.82 and 7.81 mu M, respectively. While tumor growth was continued in the control group, the tumor volume decreased in the treatment group. All results point to the conclusion that the new compound has the potential to treat solid tumors.en_US
dc.description.sponsorshipEge University Scientific Research Projects Office [16 FEN 007]en_US
dc.description.sponsorshipThis publication was produced from Habibe YILMAZ?s doctoral dissertation and financially supported by Ege University Scientific Research Projects Office with the project number 16 FEN 007.en_US
dc.identifier.doi10.1590/s2175-97902022e20954
dc.identifier.issn1984-8250
dc.identifier.issn2175-9790
dc.identifier.urihttps://doi.org/10.1590/s2175-97902022e20954
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23187
dc.identifier.volume58en_US
dc.identifier.wosWOS:000919873800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherUniv Sao Paulo, Conjunto Quimicasen_US
dc.relation.ispartofBrazilian Journal Of Pharmaceutical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPlatinum-Derivativeen_US
dc.subject4-Hydroxybenzoic Aciden_US
dc.subjectAnti-Cancer Agenten_US
dc.subjectXenograft Modelen_US
dc.subjectLung Canceren_US
dc.subjectProtein-Bindingen_US
dc.subjectCisplatinen_US
dc.subjectTissuesen_US
dc.subjectPlasmaen_US
dc.subjectAciden_US
dc.titleA novel second-generation platinum derivative and evaluation of its anti-cancer potentialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu